Literature DB >> 31695300

Mean standardized uptake value (SUVmean) and global hepatic glycolysis as potential imaging markers reflecting hepatic functional capacity: evidence from 18F-FDG PET/CT.

X Yue1, J Wang1, F Ye1, D Xiao1.   

Abstract

BACKGROUND: Hepatic cirrhosis caused by hepatic steatosis and hepatitis is irreversible. Early and non-invasive diagnosis of these diffuse hepatopathies calls for possible imaging markers. The purpose of this study was to explore the changes in global hepatic glucose metabolism following hepatic steatosis, hepatitis, or cirrhosis on 18F-2-fluoro-2-D-deoxyglucose-positron emission tomography (18F-FDG PET)/computed tomography (CT).
METHODS: A total of 178 subjects (51 healthy controls, 41 patients with hepatic steatosis, 50 patients with chronic hepatitis, and 36 patients with hepatic cirrhosis) were recruited, and their hepatic 18F-FDG PET/CT images were reviewed retrospectively. The hepatic volume (HV; cm3), mean standardized uptake value (SUVmean) in the global liver, and accordingly, global hepatic glycolysis (GHG; cm3) were measured. SPSS 19.0 was used for statistical analysis with ANOVA and LSD t-tests, and p <0.05 was considered statistically significant.
RESULTS: Statistical differences were observed in SUVmean among the hepatic steatosis group (2.44 ± 0.40), hepatitis group (2.47 ±0 .37), control group (2.23 ± 0.42), and hepatic cirrhosis group (2.01 ± 0.36) except between the steatosis group and hepatitis group. Statistical differences were observed in GHG among the hepatic steatosis group (2,918.44 ± 962.67), hepatitis group (2,466.66 ± 668.33), control group (2,230.46 ± 549.47), and hepatic cirrhosis group (1,693.81 ± 666.21) except between the hepatitis group and control group.
CONCLUSIONS: SUVmean, together with GHG, can reflect hepatic functional capacity, which can be regarded as potential imaging markers in assessing diffuse hepatopathies. HIPPOKRATIA 2018, 22(4): 162-166. Copyright 2018, Hippokratio General Hospital of Thessaloniki.

Entities:  

Keywords:  18F-FDG PET/CT; computed tomography; global hepatic glycolysis; hepatic functional capacity; positron emission tomography; standardized uptake value

Year:  2018        PMID: 31695300      PMCID: PMC6825420     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  25 in total

Review 1.  Cirrhosis reversal: a duel between dogma and myth.

Authors:  Valeer J Desmet; Tania Roskams
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

2.  Ultrasonic diagnosis and vasoactive substances examination in patients with cirrhosis.

Authors:  Mei Fan; Chun Su; Lin Lu; Jun-Chang Qin; Pei Li; Jia-Ying Yuan
Journal:  Asian Pac J Trop Med       Date:  2014-04       Impact factor: 1.226

3.  The combined effects of serum lipids, BMI, and fatty liver on 18F-FDG uptake in the liver in a large population from China: an 18F-FDG-PET/CT study.

Authors:  Guobing Liu; Yanli Li; Pengcheng Hu; Dengfeng Cheng; Hongcheng Shi
Journal:  Nucl Med Commun       Date:  2015-07       Impact factor: 1.690

4.  Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis.

Authors:  I R Wanless; E Nakashima; M Sherman
Journal:  Arch Pathol Lab Med       Date:  2000-11       Impact factor: 5.534

5.  Hepatic steatosis is associated with increased hepatic FDG uptake.

Authors:  Georgia Keramida; Jon Potts; Janice Bush; Sabina Dizdarevic; A Michael Peters
Journal:  Eur J Radiol       Date:  2014-02-07       Impact factor: 3.528

6.  Focal confluent fibrosis in cirrhotic liver: natural history studied with serial CT.

Authors:  Giuseppe Brancatelli; Richard L Baron; Michael P Federle; Gianvincenzo Sparacia; Karen Pealer
Journal:  AJR Am J Roentgenol       Date:  2009-05       Impact factor: 3.959

7.  MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: does histologic necroinflammation influence the measurement of hepatic stiffness?

Authors:  Yu Shi; Qiyong Guo; Fei Xia; Bogdan Dzyubak; Kevin J Glaser; Qiuju Li; Jiahui Li; Richard L Ehman
Journal:  Radiology       Date:  2014-06-02       Impact factor: 11.105

8.  Quantitative assessment of global hepatic glycolysis in patients with cirrhosis and normal controls using 18F-FDG-PET/CT: a pilot study.

Authors:  Ana Hernandez-Martinez; Victor A Marin-Oyaga; Ali Salavati; Babak Saboury; Ion Codreanu; Marnix G E H Lam; Drew A Torigian; Abass Alavi
Journal:  Ann Nucl Med       Date:  2013-10-27       Impact factor: 2.668

9.  Quantitative assessment of the hepatic metabolic volume product in patients with diffuse hepatic steatosis and normal controls through use of FDG-PET and MR imaging: a novel concept.

Authors:  Gonca G Bural; Drew A Torigian; Anne Burke; Mohamed Houseni; Khaled Alkhawaldeh; Andrew Cucchiara; Sandip Basu; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2009-10-06       Impact factor: 3.488

10.  Metabolic liver function measured in vivo by dynamic (18)F-FDGal PET/CT without arterial blood sampling.

Authors:  Jacob Horsager; Ole Lajord Munk; Michael Sørensen
Journal:  EJNMMI Res       Date:  2015-05-14       Impact factor: 3.138

View more
  2 in total

1.  Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study.

Authors:  Zhong-Wei Chen; Kun Tang; You-Fan Zhao; Yang-Zong Chen; Liang-Jie Tang; Gang Li; Ou-Yang Huang; Xiao-Dong Wang; Giovanni Targher; Christopher D Byrne; Xiang-Wu Zheng; Ming-Hua Zheng
Journal:  Int J Med Sci       Date:  2021-09-07       Impact factor: 3.738

2.  Predicting the Recurrence of Hepatocellular Carcinoma after Primary Living Donor Liver Transplantation Using Metabolic Parameters Obtained from 18F-FDG PET/CT.

Authors:  Sungmin Kang; Joo Dong Kim; Dong Lak Choi; Byungwook Choi
Journal:  J Clin Med       Date:  2022-01-12       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.